[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"daptdual-antiplatelet-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:daptdual-antiplatelet-therapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,71,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006",false,"NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.","ALL","18 Years",{"count":19,"type":20},462,"ESTIMATED","OBSERVATIONAL","Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[24,25,26,27,28],"Stroke","Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","Acute Ischemic Stroke",[30,31,25,32,33],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","NOT_YET_RECRUITING","2025-12-10",{"date":37,"type":38},"2025-12-23","ACTUAL",{"date":40,"type":20},"2026-01-01",{"date":42,"type":20},"2026-04-30",{"name":44,"class":45},"Sigmund Freud PrivatUniversitat","OTHER",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100603716","dual-anti-platelet-optimized-stent-for-high-bleeding-risk-patient-100603716","NCT07140133","Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient","DIOHR","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Male or female patient requiring a coronary angioplasty procedure according to European recommendations,\n* Patients undergoing revascularization with HT-supreme stents\n* Patient at high risk of bleeding according to ARC HBR definition (9).\n* Patient affiliated to or benefiting from a social security scheme\n* Patient who does not object to research\n\nExclusion Criteria:\n\n* Estimated lifespan \\\u003C1 year,\n* Allergy and any other contraindication to aspirin and\u002For clopidogrel listed in the summary of product characteristics,\n* Allergy to iodinated contrast media\n* Adults under legal protection (guardianship, curatorship or safeguard of justice).\n* Persons deprived of their liberty by judicial or administrative decision,\n* Patient in a period of relative exclusion from another research protocol,",{"count":55,"type":20},1200,"High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events, particularly in HBR patients, compared with longer DAPT. European guidelines therefore authorize one-month DAPT in HBR patients presenting even an acute coronary syndrome.\n\nThe HT Supreme Drug Coated Coronary Stent System (HT Supreme DES) is designed to promote reendothelialization as quickly as possible. That's why the stent is called \"HT\" Supreme, with \"HT\" standing for \"Healing Targeted\", enabling a DAPT of just 1 month in all-comers HBR patients.\n\nThanks to these features, the investigators aim to demonstrate ischemic and hemorrhagic complication rates lower than those found in the literature with other stent.",[58,59,60,26],"High Bleeding Risk Patients","Cardiology","Stent Implantation","2025-08-21",{"date":63,"type":38},"2025-08-24",{"date":65,"type":20},"2025-09",{"date":67,"type":20},"2027-09",{"name":69,"class":45},"University Hospital, Grenoble",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100594822","comparison-of-cardiovascular-risks-between-hip-fracture-surgery-with-continued-daptdual-antiplatelet-therapy--within-6-weeks-vs-after-6-weeks-post-pcipercutaneous-coronary-intervention-a-prospective-observational-cohort-study-100594822","NCT07024446","Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study","Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued （Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study","Inclusion Criteria:\n\nNormal hs-cTnI levels prior to NCS BMI 20-28 kg\u002Fm² Post-PCI procedure, currently on regular DAPT therapy Complete PCI procedural documentation (date, quantity, stent type) Mentally sound, capable of normal communication\n\nExclusion Criteria:\n\nAbnormal hs-cTnI before NCS; Accompanied by dysfunction of other organs History of other major surgeries Risk factors for stent thrombosis (age \\>79 years, impaired left ventricular function, stent implantation due to acute coronary syndrome, multiple stents, diabetes, renal insufficiency with creatinine \\>1.5 mg\u002Fdl) Abnormal coagulation function Local anesthesia surgery Inability to cooperate","79 Years",{"count":80,"type":20},50,"Percutaneous coronary intervention (PCI) is commonly used to treat stable ischemic heart disease. Among patients, 7.5% require surgical treatment, and up to 20% may need noncardiac surgery (NCS) within two years.\n\nCompared to patients without coronary stents, those requiring NCS shortly after PCI face an increased risk of perioperative major adverse cardiac and cerebrovascular events (MACCE), primarily manifested as thrombotic and bleeding events. Guidelines recommend 6-12 months of dual antiplatelet therapy (DAPT) post-PCI to prevent stent thrombosis, which is associated with an elevated risk of perioperative bleeding during NCS. Multiple retrospective studies suggest that the incidence of MACCE decreases as the interval between PCI and NCS lengthens, reaching a risk level similar to non-PCI patients after 12 months. However, other studies indicate that the risk in patients with similar PCI-NCS intervals correlates more with surgical complexity and urgency. Guidelines advise adequate antiplatelet therapy post-PCI to prevent stent thrombosis and recommend avoiding elective surgery within 4-6 weeks after PCI, contingent on bleeding and thrombotic risk assessments.\n\nMany post-PCI patients facing NCS option to delay surgery after weighing the risks of discontinuing antiplatelet therapy versus postponement, which not only reduces quality of life but also increases the risks associated with delayed surgery. Additionally, retrospective studies have found that in unavoidable emergency or time-sensitive surgeries, the heightened perioperative cardiovascular risk is primarily due to the underlying surgical condition affecting organ function, rather than the PCI-NCS interval or antiplatelet therapy discontinuation.\n\nRecent advancements in minimally invasive surgical techniques have reduced trauma and bleeding, leading to broader indications for surgery in patients on anticoagulant or antiplatelet therapy. The widespread use of newer-generation drug-eluting stents (DES) with advanced antiproliferative drugs has further lowered stent thrombosis rates. Moreover, refined PCI techniques minimize vascular injury during stent placement, reducing the likelihood of extra-stent restenosis. From an anesthesiology perspective, concerns for post-PCI surgical patients extend beyond bleeding risks to whether cardiac function can withstand perioperative hemodynamic changes. As surgical and anesthetic techniques evolve, traditional single-method anesthesia is increasingly replaced by combined techniques that ensure adequate analgesia while minimizing hemodynamic disturbances, maintaining oxygen supply-demand balance, and reducing ischemic and bleeding events.\n\nHip fractures in elderly patients, often termed the \"last fracture in life,\" carry high surgical and anesthetic risks for those with coronary artery disease. While PCI addresses coronary stenosis, the use or discontinuation of antiplatelet therapy exposes patients to bleeding and ischemic risks. The optimal timing for hip fracture surgery is within 48 hours; delays may lead to malunion, prolonged bedrest complications (e.g., pressure sores, pneumonia), and increased deep vein thrombosis risk. Modern hip fracture surgeries (e.g., internal fixation, hip replacement, Proximal femoral nail antirotation internal fixation) are well-established, with reduced bleeding and faster recovery, making it feasible to perform surgery without interrupting antiplatelet therapy.\n\nExisting research primarily consists of retrospective analyses of cardiovascular risk prediction in post-PCI patients undergoing NCS, with no recent prospective studies. Guideline recommendations on PCI-NCS intervals remain unchanged since 2016. Consequently, many PCI patients must delay surgery, enduring unpredictable risks and diminished quality of life.\n\nThis study aims to prospectively observe the incidence of MACCE in hip fracture surgery performed within six weeks post-PCI without discontinuing DAPT. The findings may provide evidence for the feasibility of early post-PCI surgery, offer clinicians and patients safer antithrombotic strategies, and present a new option to improve patient quality of life.",[83,26,84],"PCI Patients","Hip Fracture Surgeries","2025-06-09",{"date":87,"type":38},"2025-06-17",{"date":89,"type":20},"2025-07-01",{"date":91,"type":20},"2027-07-01",{"name":93,"class":45},"Fujian Medical University Union Hospital",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100516645","phase-4-non-antithrombotic-therapy-after-transcatheter-aortic-valve-implantation-trial-100516645","NCT06007222","Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial","Inclusion Criteria:\n\n1. Patients who underwent transfemoral TAVI for aortic stenosis\n2. Patients aged 20 years or older at the time of informed consent\n3. Patients who have a thorough understanding of the subject of the study and who have agreed in writing to participate in the study\n\nExclusion Criteria:\n\n1. Those with perioperative complications at the time of TAVI (conversion to open heart surgery, coronary artery occlusion, annulus rupture, cardiac tamponade, vascular dissection, cerebral infarction\u002Fcerebral hemorrhage, new atrial fibrillation, new atrioventricular block)\n2. Individuals requiring antiplatelet agents for reasons other than TAVI (history of myocardial infraction, history of PCI（Percutaneous Coronary Intervention）, history of EVT（EndoVascular Treatment）, history of cerebral infraction and transient ischaemic stroke, with significant coronary artery narrowing, with high-grade carotid artery narrowing, and others judged as requiring antiplatelet therapy by the chief researcher or a sub-investigator)\n3. Patients requiring oral anticoagulants (patients with atrial fibrillation, history of pulmonary embolism or deep venous thrombosis, and other patients who are deemed to require anticoagulation therapy by the investigator or coinvestigator)\n4. Patients with eGFR（estimated Glomerular Filtration Rate） \\\u003C30 and patients on hemodialysis\u002Fperitoneal dialysis.\n5. Patients with a history of valve replacement in the heart valves.\n6. Patients who are pregnant, have childbearing potential, wish to become pregnant, or are breastfeeding.\n7. Patients who have a concomitant medical illness associated with expected survival less than one year.\n8. Patients who have the contraindications for aspirin.\n9. Patients with a diagnosis of severe allergy to aspirin or a history of hypersensitivity.\n10. Patients requiring a legally acceptable representative, patients unable to obtain written informed consent, or patients unable to understand the outline or purpose of the study.\n11. Other patients for whom the principal investigator or the coinvestigator judges the participation in the study inappropriate.","20 Years",{"count":102,"type":20},400,"INTERVENTIONAL",[105],"PHASE4","Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg\u002Fday the end of the study period.\n\nNon-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.",[108,109,110,26,27],"Aortic Stenosis","TAVI(Transcatheter Aortic Valve Implantation)","Aspirin","RECRUITING","2024-09-20",{"date":114,"type":38},"2024-09-23",{"date":116,"type":38},"2023-04-06",{"date":118,"type":20},"2027-12-31",{"name":120,"class":45},"OCEAN-SHD Study Group"]